Astel­las swoops in on a mid-stage drug for hot flash­es in $860M biotech buy­out deal

Three months af­ter the Bel­gian biotech Oge­da re­port­ed solid­ly pos­i­tive da­ta from a Phase IIa study of its ex­per­i­men­tal, non-hor­mon­al ther­a­py for hot flash­es re­lat­ed to menopause, the com­pa­ny is be­ing bought out with a hefty cash pay­ment of €500 mil­lion along with a com­mit­ment for €300 mil­lion more in mile­stones (or about $860 mil­lion to­tal).

Japan’s Astel­las has swooped in to make the buy­out, ob­vi­ous­ly im­pressed with da­ta that showed a 93% re­duc­tion in hot flash­es for the fe­zo­line­tant group at week 12 com­pared to 54% on place­bo. The re­duc­tion in sever­i­ty of hot flash­es at week 12 was 70% for the drug arm and 23% in the place­bo group.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.